Feb 12, 2021 11:35am To evaluate the test’s accuracy against new coronavirus mutations, BD used computer modeling to show that 99.9% of the altered genetic sequences would still match up to the targets used in its tests. (Getty/RossHelen) BD has secured U.S. and European authorizations for a new COVID-19 test that screens for the coronavirus as well as influenza A and B—and the company said it’s shown to work against the emerging variants first identified in the U.K. and South Africa. The molecular laboratory test is designed to turn around results in two to three hours, and process hundreds of samples per day on the company’s BD MAX platform.